The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Por Honigberg, Lee A., Smith, Ashley M., Sirisawad, Mint, Verner, Erik, Loury, David, Chang, Betty, Li, Shyr, Pan, Zhengying, Thamm, Douglas H., Miller, Richard A., Buggy, Joseph J.
Publicado em 2010

Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

Por Zhong, Yiming, Dong, Shuai, Strattan, Ethan, Ren, Li, Butchar, Jonathan P., Thornton, Kelsey, Mishra, Anjali, Porcu, Pierluigi, Bradshaw, J. Michael, Bisconte, Angelina, Owens, Timothy D., Verner, Erik, Brameld, Ken A., Funk, Jens Oliver, Hill, Ronald J., Johnson, Amy J., Dubovsky, Jason A.
Publicado no J Biol Chem (2015)

Prolonged and tunable residence time using reversible covalent kinase inhibitors

Por Bradshaw, J. Michael, McFarland, Jesse M., Paavilainen, Ville O., Bisconte, Angelina, Tam, Danny, Phan, Vernon T., Romanov, Sergei, Finkle, David, Shu, Jin, Patel, Vaishali, Ton, Tony, Li, Xiaoyan, Loughhead, David G., Nunn, Philip A., Karr, Dane E., Gerritsen, Mary E., Funk, Jens Oliver, Owens, Timothy D., Verner, Erik, Brameld, Ken A., Hill, Ronald J., Goldstein, David M., Taunton, Jack
Publicado no Nat Chem Biol (2015)